Corticosteroids Linked to Pneumonia Ivanhoe, FL - (Ivanhoe Newswire) -- Inhaling corticosteroids to treat chronic obstructive pulmonary disease (COPD) may cause pneumonia, a new study shows. ...
Inhaled Corticosteroids in Patients With Stable Chronic ... Journal of American Medical Association (subscription), IL - Nov 25, 2008 ... MD; Eddy Fan, MD Context Recent studies of inhaled corticosteroid (ICS) therapy for managing stable chronic obstructive pulmonary disease (COPD) have ...
Inhaled Corticosteroids May Not Reduce Mortality in COPD Medscape - Nov 25, 2008 Compare the effect of inhaled corticosteroids with control treatment on 1-year mortality rate in patients with chronic obstructive pulmonary disease. ...
Learn about the World Ophthalmic Pharmaceutical Drugs Market MarketWatch - Nov 25, 2008 II-2 In the Shifting Demographics II-2 Which Disease Segment Offers Abundant Opportunities for R&D Initiatives II-3 Leading Companies & Their Areas of ...
Source: Google News
Recent News and Articles on the Keywords: 0.37 + 62,100 + oral Related to the article below (Last Update: 8/7/2008)
Sun Hydraulics Can?t Jack Earnings Up Enough (SNHY) Dividend.com, NJ - Aug 5, 2008 New EPS estimates are in the range of $0.35-0.37, below the $0.42 number analysts had been expecting. Equipment used in residential and commercial ...SNHY
SPITZ BACKING PHELPS BID Sportinglife.com, UK - Phelps holds four world records out of five individual events, with Ian Crocker in possession of the 100m butterfly best of 50.40 seconds, 0.37secs better ...
Effect of One-year Oral a-Tocopherol Administration on the Antioxidant Defense System in … G Antoniadi, T Eleftheriadis, V Liakopoulos, E … - Therapeutic Apheresis and Dialysis, 2008 - Blackwell Synergy ... of Serres, 3rd km Serres-Dramma, 62100 Serres, Greece ... were measured before and after
its oral administration for ... 1.31 ? 0.37 mmol/L; P < 0.001, unpaired t-test ... -
E-learning: using standards and reengineering techniques to maintain programme quality - S Haugen, R Behling - International Journal of Innovation and Learning, 2006 - Inderscience ... even though they may be skilled in oral communications, and the ... 8 hours or less 0.25
0.10 0.37... com/careertopics/careers/training/story/0,10801,62100,0/html. ...
[PDF]Bioavailability of arsenic and lead in environmental substrates - RM Lorenzana, B Duncan, RE Branch, M Ketterer, J … - Superfund/Office of Environmental Assessment, Region, 1996 - epa.gov ... as test animals was performed to determine if arsenic and lead were absorbed from
the gastrointestinal tract into the bloodstream following oral dosing of soil ...
[PDF]Water Use of Woody Crops Water Use of Woody Crops P ?lhavo - isa.utl.pt ... 2 ABSTRACTS of oral presentations Page 8. ... (corresp. cermak@mendelu.cz). 2 Environmental
Measuring Systems, Turistick? 5, 62100 Brno, Czech Republic ...
[PDF]Dynamics of recovery MR Council - Mattole Restoration Council, Petrolia, California, 1995 - krisweb.com Page 1. Dynamics of Recovery A Plan to Enhance the Mattole Estuary Mattole
Restoration Council scanned for KRIS Page 2. Dynamics of Recovery ...
[CITATION] RESISTENCIA ? SECA EM SERINGUEIRA sentaran os menores n?meros de ?blhas e lan?a-mentos, … ? ?? - Pesquisa agropecu? aria brasileira, 1977 - Empresa Brasileira de Pesquisa Agropecu?ria -
Source: Google Scholar
Most patients receiving prolonged oral corticosteroids for chronic skin diseases do not receive therapy to prevent osteoporosis
In a small study, most patients receiving prolonged oral corticosteroids for chronic skin diseases were not receiving therapies to prevent osteoporosis that may be caused by the drug.
The study is published in the Archives of Dermatology.
Oral glucocorticoids, or corticosteriods, are prescribed for a variety of chronic skin diseases, as well as other conditions.
" Independent of the reason for their use, all patients receiving long-term glucocorticoid treatment have an increased risk of developing osteoporosis," a decrease in bone mass that can lead to fractures, the authors report.
Research has demonstrated that medications known as bisphosphonates can boost bone mineral density ( BMD ) and help reduce the risk of osteoporosis.
Rosemarie H. Liu, Eastern Virginia Medical School, Norfolk, and colleagues reviewed 35 patients with chronic skin diseases referred to the Hospital of the University of Pennsylvania after October 1995.
Each was taking glucocorticoids for at least one month before they were referred.
The researchers obtained information about the participants' prescriptions during their clinic visits, by reviewing medical records and sometimes by telephone.
Twenty-eight ( 80 percent ) of the patients were not taking bisphosphonates at the time they were referred.
" The low rate of bisphosphonate use prior to referral and prolonged time interval until initiation of prophylaxis are disappointing because bisphosphonates are agreed to be the most efficacious agents known to prevent glucocorticoid-induced osteoporosis ( GIOP )," the authors report. " This may be due to variations in knowledge about GIOP among different physician specialties."
" Unless there is a specific contraindication, bisphosphonates should be prescribed concomitantly with the initiation of corticosteroid therapy in diseases for which long-term glucocorticoid use is anticipated as part of the standard of care," they conclude.
